Quality of life level in patients with diffuse large B-cell lymphoma from high-risk group treated with R-DA-EPOCH regimen
Summary. Chemotherapy (CT) intensification can influence on quality of life (QOL) level. QOL was assessed in prospective cohort multicenter study in patients with diffuse large B-cell lymphoma from high-risk group treated with СНОР-like regimens (І group), R-CHOP (ІІ group), and R-DA-EPOCH (ІІІ group). We have compared the QOL levels before and after CT with visual scale of EQ-5D-3L questionnaire. Treatment efficacy was comparable in all groups. Anemia was observed more frequently in І group, neutropenia grade III–IV, neuropathy and transaminase elevation — in III group. QOL was assessed in 40 patients (3 — in І group, 22 — in II group and 15 — in III group). QOL before the treatment in І group was 40%, in ІІ group — 60%, in ІІІ group — 70% (p=0,06). QOL after the end of the therapy was 60; 67.5 and 78%, respectively (p=0,32). Thus, we did not observed statistically significant difference between the groups. QOL changes were statistically significant in all groups (p=0,02). Therefore, treatment with R-DA-EPOCH regimen in diffuse large B-cell lymphoma patients from high-risk group did not decrease the QOL comparing to other regimens.
No Comments » Add your